Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 3/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.34 |
| ▸ | DRD2 | P14416 | 6/20 | 0.33 |
| ▸ | DRD4 | P21917 | 6/20 | 0.33 |
| ▸ | DRD3 | P35462 | 6/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | RECQL | P46063 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | SPHK2 | Q9NRA0 | 1/20 | 0.30 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.30 |
| ▸ | NAMPT | P43490 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20127154 | 0.89 | SPHK2 (0.33) | TSHRMEN1KMT2AALDH1A1DRD2 | |
| SCHEMBL5933549 | 0.87 | HSD17B10 (0.33) | TSHRMEN1KMT2AALDH1A1 | |
| SCHEMBL15510923 | 0.83 | ALDH1A1 (0.37) | TSHRMEN1KMT2AALDH1A1KDM4E | |
| SCHEMBL23875671 | 0.82 | MEN1 (0.33) | MEN1KMT2AKDM4ERECQL | |
| SCHEMBL25728535 | 0.82 | CYP2C19 (0.41) | TSHRMEN1KMT2AKDM4E | |
| SCHEMBL24978972 | 0.82 | CA12 (0.46) | TSHRMEN1KMT2ARECQLSMN1; SMN2 | |
| SCHEMBL11456186 | 0.82 | ALDH1A1 (0.40) | TSHRMEN1KMT2AALDH1A1KDM4E | |
| SCHEMBL18908743 | 0.81 | MEN1 (0.35) | TSHRMEN1KMT2AKDM4ERECQL | |
| SCHEMBL21480809 | 0.81 | SCN1A (0.37) | MEN1KMT2AALDH1A1 | |
| SCHEMBL21106801 | 0.81 | MEN1 (0.35) | TSHRMEN1KMT2AKDM4ERECQL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180134843-A1 | AQUEOUS POLYGLYCIDOL SYNTHESIS WITH ULTRA-LOW BRANCHING | VANDERBILT UNIVERSITY | 2018-05-17 | — | — | US | disclosed |
| US-20180125983-A1 | Linear Polyester and Semi-Linear Glycidol Polymer Systems: Formulation and Synthesis of Novel Monomers and Macromolecular Structures | UNIV VANDERBILT (US) | 2018-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180125983-A1 | Linear Polyester and Semi-Linear Glycidol Polymer Systems: Formulation and Synthesis of Novel Monomers and Macromolecular Structures | STT3A, STT3B, B3GAT3 | TSHR 2588/4885MEN1 2164/4885KMT2A 2891/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.